Want to discover why and how pigs are becoming the must-have preclinical model for accelerating development of cancer therapies?
In this video you will learn:
- Unrivaled advantages of pigs vs traditional animal models
- Why pigs are essential preclinical platforms for gene therapy, rare disease, pediatric cancers, and more
- The "nuts-and-bolts" of genetically engineering pigs
- Case study on how pigs have augmented mouse models and enabled critical PK/PD studies for Neurofibromatosis Type 1
- Harnessing human genetic drivers to induce solid tumors in pigs
- Using pigs for biomarker discovery
- Late breaking!... new models for Glioblastoma and hepatocellular carcinoma
- Getting started…. planning for pig models in your new studies
Speaker: Adrienne Watson, PhD, VP R&D of Surrogen (division of Recombinetics)
Expert in gene-editing technology for swine models of human diseases with a focus on cancer, neurodegenerative diseases, and regenerative medicine. Utilized Sleeping Beauty transposon system in animal models to develop new animal models, uncover targeted therapy candidates, and identify novel cancer genes and pathways. Ph.D. in Molecular, Cellular, Developmental Biology and Genetics at the Univ MN. Post-Doc at University of Minnesota Masonic Cancer Center.
Surrogen is a world leader in gene edited pigs and disease models to accelerate new therapeutics and med devices development.
Host: William Kazman, Founding Partner of GeneWorx Capital
MIT-trained engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact. Applying 30+ years of engineering and company-building skills to identify early stage biological innovations with disruptive potential, and help their inventors/scientists/entrepreneurs transform them into high value enterprises.
GeneWorx Capital is a venture development firm in Cambridge, MA comprised of MIT technologists, former Wall Street VC investors and Silicon Valley entrepreneurs on a mission to accelerate the growth of emerging life science companies.